RICHMOND, Calif., April 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. , a leader in the research and development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, announced today the appointment of Stephen G. Dilly, M.B.B.S., Ph.D., to the company's board of directors effective March 31, 2010.
Dr. Stephen G. Dilly is currently President, Chief Executive Officer and a member of the board of directors of APT Pharmaceuticals, Inc., a specialty drug company which is currently conducting a Phase III clinical trial of inhaled cyclosporine for the prevention and treatment of chronic rejection in lung transplantation. Before joining APT in 2006, Dr. Dilly was Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003, he held various senior management positions at Genentech Inc., including Vice President of Development Sciences, and in the ten years prior held senior management positions in drug development with SmithKline Beecham in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin.
Dr. Dilly also serves as a member of the Advisory Board of Physic Ventures and the National Board of Advisors of the UC Davis Health System. Dr. Dilly earned his M.B.B.S., or the equivalent of an M.D. in the U.S., from the University of London in the U.K. and received his Ph.D. in Cardiac Physiology from University of London.
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the development of Sangamo's clinical pipeline, establishing Sangamo's ZFP technology as a novel therapeutic product development platform and election of directors. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Sangamo BioSciences, Inc.
